Solventum (NYSE:SOLV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Solventum (NYSE:SOLV) from a hold rating to a buy rating in a research report released on Saturday.

Several other equities analysts have also recently commented on SOLV. Wedbush increased their target price on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. BMO Capital Markets assumed coverage on shares of Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target for the company. Mizuho set a $113.00 price objective on shares of Solventum in a research note on Thursday. Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 17th. Finally, UBS Group increased their price target on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $91.64.

Solventum Stock Up 2.9%

Shares of Solventum stock opened at $85.38 on Friday. The business has a 50-day moving average of $79.58 and a 200-day moving average of $74.45. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. The company has a market capitalization of $14.53 billion, a PE ratio of 10.44, a P/E/G ratio of 1.06 and a beta of 0.60. Solventum has a 1-year low of $62.38 and a 1-year high of $90.00.

Solventum (NYSE:SOLV) last announced its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same period in the previous year, the company earned $1.69 earnings per share. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities analysts forecast that Solventum will post 7.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Solventum

Institutional investors and hedge funds have recently bought and sold shares of the business. CrossGen Wealth LLC acquired a new position in Solventum in the fourth quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Solventum in the 3rd quarter worth approximately $25,000. JNBA Financial Advisors boosted its position in Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares during the period. CYBER HORNET ETFs LLC acquired a new position in Solventum during the 2nd quarter valued at approximately $28,000. Finally, Modus Advisors LLC bought a new position in Solventum during the 4th quarter worth $30,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.